During the nomination hearing held on April 30, President Donald Trump’s choice to head the Drug Enforcement Administration, or DEA, provided marijuana rescheduling supporters with both optimism as well as concern.
Terry Cole was a DEA Veteran who Trump Nominated In February, when he was confirmed as the next administrator of the DEA, he told members of the U.S. Senate Judiciary Committee that “it will be my first priority” to examine where the DEA stands in the administrative procedure to reschedule marijuana.
Trump’s permanent DEA director aligns himself with Nancy Reagan’s War on Drugs Campaign
Currently, an ALJ process is being conducted by the DEA to hear the Department of Justice’s proposal to reclassify marijuana from Schedule I under the Controlled Substances Act to Schedule III. delayed Interlocutory appeal
“I am not sure where we are but I do know that the process is being delayed and now it’s the right time to get moving,” Cole stated to Senator Alex Padilla of California during the hearing. The confirmation also included Gady Serralta who was Trump’s choice to become director of U.S. Customs. Marshals Service.
Schedule III is a proposal that dates back to October 20, 2022. President Joe Biden instructed his Cabinet to launch an administrative process in order to examine how cannabis was classified under federal law.
Upon his presumptive confirmation, Cole would be responsible for setting a briefing schedule to allow the hearing’s designated participants to file briefs with the DEA concerning the interlocutory appeal—which accuses the DEA of improper communications with anti-rescheduling participants—before a stay can be lifted on the hearing process.
Cole, if he so “desires,” could hear oral arguments and issue a written, binding decision on whether the appeal should continue. This would be sent to Judge John J. Mullrooney of the DEA, the chief ALJ.
Cole, who said he supports moving forward with the Schedule III rule proposal during his confirmation hearing, declined to respond when Padilla asked him if he would be committed to see it through “fruition.”
“Cole stated that he needed to “understand more about where the people are, look at the science and the experts behind it as well as listen to them and understand exactly where they were in the process.”
“We are aware of where we are. It is clear what our directive is. Get the item on Schedule III. “Are you dedicated to see it through?” Padilla asked again.
“I don’t really know.” Cole responded, “I’ve never seen it sir.”
“So, you’re leaving the door open to changing course as to—?” Padilla asked.
Cole replied: “I will study everything done to date so that I may make a decision, sir.”
“So, make myself a note here—no answer to that particular question,” Padilla said.
The U.S. Department of Health and Human Services determined that in August 2023, after a medical and scientific evaluation, cannabis had a low potential for abuse and was currently used as a medical treatment in the U.S. Recommendations Reclassification of the substance as Schedule III.
The former Attorney General Merrick G. Garland has signed the proposed rule. However, the DEA is yet to make a commitment to it despite being the “proponent”.
After the ALJ hearing—should it resume and conclude—Mulrooney’s job is to provide the DEA with his recommendation for whether to issue a final rule that’s consistent with the proposed rule; however, that decision is ultimately up to the DEA administrator unless U.S. Attorney General Pam Bondi redelegates the DEA’s rescheduling authority to herself.
Some argue that while the Attorney General traditionally delegated his or her rescheduling power to the DEA to release a final ruling on the current proposal for cannabis rescheduling under the Biden Administration, Garland did not do so.
Rescheduling hearings could be delayed if the Attorney General’s authority to do so is not delegated, lawyers argue.
The Trump administration is in charge of a scheduling process started by Biden. Trump may be a partisan, but he is not the only one. Signal How far President Obama is prepared to go in order to affect policy regarding cannabis remains unknown.
Cannabis policies are often put on hold by the elected and appointed leaders of our country, even though there are industries in distress that would benefit greatly from a rescheduling.
Cole said that during the hearing on Wednesday, his priority was to secure U.S. border and draw from 30 years of law enforcement expertise. If confirmed, Cole’s top priority as DEA Administrator will be combating the fentanyl epidemic by securing U.S. border and drawing from his 30 years of law enforcement expertise that have given him a unique perspective on the cartel-driven destruction affecting our community.
In his first statement, he didn’t refer to the cannabis policy.
Cole’s 30-year law-enforcement career is a reflection of his character. The following are some of the ways to get in touch with each other in February 2024 that “everybody knows my stance on marijuana … so don’t even ask.”
During the nomination hearing held on April 30, President Donald Trump’s choice to head the Drug Enforcement Administration, or DEA, provided marijuana rescheduling supporters with both optimism as well as concern.
Terry Cole was a DEA Veteran who Trump Nominated In February, when he was confirmed as the next administrator of the agency, DEA Director Richard Clarke told the U.S. Senate Judiciary Committee that rescheduling cannabis would be “one of my top priorities.”
Trump picks a permanent DEA administrator who aligns with Nancy Reagan’s War on Drugs Campaign
Currently the DEA’s Administrative Law Judge (ALJ), hearing process is underway to determine the merits of Department of Justice’s proposal to reclassify Cannabis from Schedule I under the Controlled Substances Act to Schedule III. delayed Interlocutory appeal
“I am not sure where we are but I do know that the process is being delayed and now it’s the right time to get moving,” Cole stated to Senator Alex Padilla of California during the hearing. The confirmation also included Gady Serralta who was Trump’s choice to become director of U.S. Customs. Marshals Service.
Schedule III is a proposal that dates back to October 20, 2022. President Joe Biden instructed his Cabinet to launch an administrative process in order to examine how cannabis was classified under federal law.
Upon his presumptive confirmation, Cole would be responsible for setting a briefing schedule to allow the hearing’s designated participants to file briefs with the DEA concerning the interlocutory appeal—which accuses the DEA of improper communications with anti-rescheduling participants—before a stay can be lifted on the hearing process.
Cole may, if he ‘desires,’ hear the participants present their arguments. He will then write a decision that is binding to the DEA chief ALJ Judge John J.Mulrooney on whether or not the hearings should proceed.
Cole, who said he supports moving forward with the Schedule III rule proposal during his confirmation hearing, declined to respond when Padilla questioned him if he would be committed to see it through “to fruition.”
“Cole stated that he needed to “understand more about where the people are, look at the science and the experts behind it as well as listen to them and understand exactly where they were in the process.”
“We are aware of where we are. It is clear what our directive is. Get the item on Schedule III. “Are you dedicated to see it through?” Padilla asked again.
“Well, I have no idea.” Cole replied, “I haven’t noticed that sir.”
“So, you’re leaving the door open to changing course as to—?” Padilla asked.
Cole replied: “I will study everything done to date so that I may make a decision, sir.”
“So, make myself a note here—no answer to that particular question,” Padilla said.
The U.S. Department of Health and Human Services determined that in August 2023, after a medical and scientific evaluation, cannabis had a low potential for abuse and was currently used as a medical treatment in the U.S. Recommendations Reclassification of the substance as Schedule III.
The former Attorney General Merrick G. Garland has signed the proposed rule. However, the DEA is yet to make a commitment to it despite being the “proponent”.
After the ALJ hearing—should it resume and conclude—Mulrooney’s job is to provide the DEA with his recommendation for whether to issue a final rule that’s consistent with the proposed rule; however, that decision is ultimately up to the DEA administrator unless U.S. Attorney General Pam Bondi redelegates the DEA’s rescheduling authority to herself.
Although the Attorney General typically delegate his orher rescheduling powers to the DEA for the purpose of issuing a final regulation on the Biden administration’s current cannabis rescheduling proposals, Garland may not have done so.
Rescheduling hearings could be delayed if the Attorney General’s authority to do so is not delegated, lawyers argue.
The Trump administration is in charge of a scheduling process started by Biden. Trump may be a partisan, but he is not the only one. Signal How far President Obama is prepared to go in order to affect policy regarding cannabis remains unknown.
The cannabis policy of elected and appointed government officials is frequently put on hold despite struggling industries sanctioned by the state that would benefit greatly from a rescheduling.
Cole said that during the hearing on Wednesday, his priority was to secure U.S. border and draw from 30 years of law enforcement expertise. If confirmed, Cole’s top priority as DEA Administrator will be combating the fentanyl epidemic by securing U.S. border and drawing from his 30 years of law enforcement expertise that have given him a unique perspective on the cartel-driven destruction affecting our community.
In his first statement, he didn’t refer to the cannabis policy.
Cole has a 30-year career in law enforcement behind him. The following are some of the ways to get in touch with each other in February 2024 that “everybody knows my stance on marijuana … so don’t even ask.”
Cannabis Law Resources for Poland
Discover essential legal information about the cultivation of cannabis, its sale, and regulations governing medical products in Poland. You can use these resources to learn about the requirements for certification, permissions and compliance.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland